SCHEMBL2985160

SCHEMBL2985160

CC1=NC(c2ccccc2)(c2ccccc2)C(=O)N1CCc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
SIGMAR1 Q99720 1/20 0.44
KMT2A Q03164 4/20 0.43
CYP19A1 P11511 1/20 0.43
KCNJ1 P48048 3/20 0.43
KCNH2 Q12809 2/20 0.43
BACE1 P56817 1/20 0.42
BACE2 Q9Y5Z0 1/20 0.42
PKM P14618 1/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
GFER P55789 1/20 0.41
MDM2 Q00987 2/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLC29A1 Q99808 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984449 0.83 BACE1 (0.52) BACE1BACE2
SCHEMBL2985223 0.73 MEN1 (0.46) LMNAKMT2ABACE1BACE2MEN1
SCHEMBL29531485 0.70 CA1 (0.62) SIGMAR1KCNJ1KCNH2MAPTHRH3
SCHEMBL17550101 0.70 CA1 (0.62) SIGMAR1KCNJ1KCNH2MAPTHRH3
SCHEMBL13946243 0.67 CYP1A2 (0.67) LMNASIGMAR1KMT2AKCNJ1KCNH2
SCHEMBL27583120 0.65 ALDH1A1 (0.65) LMNASIGMAR1KMT2AKCNJ1KCNH2
SCHEMBL9453685 0.64 KMT2A (0.56) SIGMAR1KMT2AKCNJ1KCNH2HRH3
SCHEMBL6953502 0.64 CA12 (0.71)
SCHEMBL28801547 0.63 KMT2A (0.65) SIGMAR1KMT2ACYP19A1KCNJ1KCNH2
Methylamine SCHEMBL27524577 0.63 SIGMAR1 (0.61) LMNASIGMAR1KMT2AKCNJ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 LMNA 2476/4885SIGMAR1 409/4885KMT2A 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.